IND SWIFT LABS chart

Last update: 2022-06-03
Key statistics and financials
Revenue per share 183.02
Dividend & YieldN/A₹ (N/A)
Beta N/A
Market capitalization 3.28B
Operating cash flow 1.5B
ESG Scores unknown

Company description

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio1.94
Working Capital-0
Return On Equity-0
Debt To Equity1.41
Fixed Asset Ratio0
Fixed Interest Cover1.13

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities
Total Cashflows From Investing Activities -124.65M -90.98M -101.72M 47.72M
Net Borrowings 1.61B -657.42M -398.53M -360.12M
Total Cash From Financing Activities 996.25M -1.33B -1.24B -1.41B
Change To Operating Activities -2.21B 335.92M 82.54M -89.06M
Issuance Of Stock 5.2M
Net Income 289.46M -211.88M -31.47M -21.49M
Change In Cash 227.6M -171.19M 10.29M 141.69M
Effect Of Exchange Rate
Total Cash From Operating Activities -644M 1.25B 1.35B 1.5B
Depreciation 1.04B 900.59M 551.67M 1.31B
Change To Account Receivables 131.37M -383.95M -384.54M -261.76M
Other Cashflows From Financing Activities -621.95M -675.17M -838.94M -1.05B
Change To Netincome 200.05M 873.79M 1.13B 1.09B
Capital Expenditures -152.56M -107.43M -39.1M -184.15M

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development
Income Before Tax 496.77M -197.71M 180.09M 125.33M
Net Income 289.46M -211.88M -31.47M -21.49M
Selling General Administrative 1.02B 1.06B 1.08B 1.14B
Gross Profit 3.76B 4.03B 4.55B 5.55B
Ebit 444.9M 739.6M 1.11B 1.08B
Operating Income 444.9M 739.6M 1.11B 1.08B
Interest Expense -839.6M -1.02B -933.53M -955.34M
Income Tax Expense 207.31M 14.17M 211.56M 146.81M
Total Revenue 7.79B 7.99B 9.07B 10.81B
Cost Of Revenue 4.03B 3.97B 4.51B 5.27B
Total Other Income ExpenseNet 51.87M -937.31M -929.51M -955.34M
Net Income From Continuing Ops 289.46M -211.88M -31.47M -21.49M
Net Income Applicable To Common Shares 289.46M -211.88M -31.47M -21.49M

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 13.36B 12.29B 12.15B 12B
Total Stockholder Equity 5.88B 6.41B 6.04B 6.01B
Other Current Liabilities 301.31M 281.04M 346.01M 538.22M
Total Assets 19.24B 18.7B 18.18B 18.01B
Common Stock 475.69M 590.87M 590.87M 598.06M
Other Current Assets 1.16B 877.85M 764.94M 1.72B
Retained Earnings 571.88M 492.44M 613.46M
Treasury Stock 2.4B 2.25B 1.76B 5.41B
Cash 299.68M 105.82M 116.01M 214.78M
Total Current Liabilities 3.56B 3.23B 3.15B 3.35B
Other Stockholder Equity 2.4B 2.25B 1.76B 5.41B
Property, Plant, and Equipment 8.45B 7.98B 7.48B 6.37B
Total Current Assets 8.36B 8.63B 9.44B 10.76B
Net Tangible Assets 5.12B 6B 5.94B 6B
Net Receivables 3.72B 4.21B 4.78B 4.55B
Accounts Payable 1.27B 1.35B 1.39B 1.76B


Insider Transactions

Here are the insider transactions of stock shares related to IND SWIFT LABS:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Chaturvedi (Anurag)Sale at price 0.95 per share.D2021-08-18UNREPORTED10.6k
Chaturvedi (Anurag)Sale at price 1.01 per share.D2021-08-16UNREPORTED10k
Chaturvedi (Anurag)Sale at price 1.34 per share.D2021-08-02UNREPORTED13.61k
Kumar (Vijay)Sale at price 0.98 per share.D2021-03-31Divisional Officer25.5k
Nag (Rajesh)Sale at price 1.09 per share.D2021-03-23UNREPORTED18k
Nag (Rajesh)Sale at price 1.17 per share.D2021-03-16UNREPORTED9.3k
Sharma (Satish)Sale at price 1.10 per share.D2021-03-15UNREPORTED10.25k
Wadhwa (Lalit K.)Sale at price 1.20 per share.D2021-03-15UNREPORTED5k
Wadhwa (Lalit K.)Sale at price 1.08 per share.D2021-03-12UNREPORTED15k
Singh (Sandeep)Sale at price 0.85 per share.D2020-12-31Vice President15.68k
Wadhwa (Lalit K.)Sale at price 0.88 per share.D2020-12-29UNREPORTED43.02k
Kumar (Ajit)Sale at price 0.83 per share.D2020-12-17UNREPORTED19k
Goel (Pradeep Kumar)Sale at price 0.83 per share.D2020-12-08Promoter1.67k
Tyagi (Saranjai)Sale at price 0.85 per share.D2020-12-03UNREPORTED23.04k
Essix Bioscience LtdD2017-12-09Promoter10.34M
AKJ Portfolios Pvt LtdD2017-12-08Promoter2.03M
GM Portfolios Pvt LtdD2017-12-08Promoter735.9k
NRM Portfolios Pvt LtdD2017-12-08Promoter1.74M
SRM Portfolios Pvt LtdD2017-12-08Promoter522.5k
VKM Portfolios Pvt LtdD2017-12-08Promoter1.15M
VRM Portfolios Pvt LtdD2017-12-08Promoter1.16M
Agarwal (Rakesh Kumar)D2017-08-21UNREPORTED6.67k
Aggarwal (Asha)D2017-08-21UNREPORTED5k
Aggarwal (Gagan)D2017-08-21UNREPORTED34k
Aggarwal (Monika)D2017-08-21UNREPORTED10k
Arora (Subhash Chander)D2017-08-21UNREPORTED6.67k
Arul (Ramakrishna)D2017-08-21UNREPORTED8k
Bahl (Atul)D2017-08-21UNREPORTED6.66k
Bahuguna (Rakesh)D2017-08-21Vice President17k
Bamba (Satish)D2017-08-21UNREPORTED20k
Bansak (Narinder Kumar)D2017-08-21UNREPORTED25k
Chakraverty (Arun)D2017-08-21UNREPORTED13.33k
Chaturvedi (Anurag)D2017-08-21UNREPORTED17k
Chaubey (Atul Kumar)D2017-08-21UNREPORTED12k
Chhabra (Varun)D2017-08-21UNREPORTED17k
Goel (Pradeep Kumar)D2017-08-21UNREPORTED31.67k
Gupta (Pranav)D2017-08-21UNREPORTED6.67k
Gupta (Subodh)D2017-08-21Director20k
Jain (Anshul Kumar)D2017-08-21UNREPORTED6.67k
Kumar (Pawan)D2017-08-21UNREPORTED5k
Kumar (Vijay)D2017-08-21Divisional Officer25k
Mahajan (Lovekesh)D2017-08-21UNREPORTED34k
Nag (Rajesh)D2017-08-21UNREPORTED25.3k
Rana (Het Ram)D2017-08-21UNREPORTED6.67k
Sarin (Gurdeep Singh)D2017-08-21UNREPORTED5k
Sharma (Gopal Krishan)D2017-08-21UNREPORTED10k
Sharma (Omkar Dutt)D2017-08-21UNREPORTED6.67k
Sharma (Satish)D2017-08-21UNREPORTED12k
Sharma (Vinod)D2017-08-21UNREPORTED6.67k
Singh (Gajendra)D2017-08-21UNREPORTED12k
Singh (Sandeep)D2017-08-21Vice President17k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to IND SWIFT LABS. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on IND SWIFT LABS

Here is the result of two systematic investment strategies applied to IND SWIFT LABS. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on IND SWIFT LABS

The following chart shows the equity curve of the two systematic investment strategies applied to IND SWIFT LABS:

IND SWIFT LABS automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 42.03% on the backtest period.

Performance at glance

Performance

42.03 %

Latent gain

1071.1 ₹

Invested capital

2548.55 ₹

Annualized return

9.96 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on IND SWIFT LABS

This is the result of two momentum investment strategies applied to IND SWIFT LABS. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on IND SWIFT LABS

The following chart shows all the entries opened by the momentum investment system on IND SWIFT LABS:

IND SWIFT LABS momentum entries
  • The first momentum investment strategy would give 41.1% of return on IND SWIFT LABS. That represents 2233.85₹ of latent gain with 5434.9₹ of employed capital.
  • The second momentum investment strategy would give 37.54% of return on IND SWIFT LABS. That represents 786.95₹ of latent gain with 2096.5₹ of employed capital.
Performance at glance (1Q Momentum)

Performance

41.1 %

Latent gain

2233.85 ₹

Invested capital

5434.9 ₹

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

37.54 %

Latent gain

786.95 ₹

Invested capital

2096.5 ₹

Annualized return

10.04 %

Momentum equity curve on IND SWIFT LABS

The following chart shows the equity curve of the two momentum strategies applied to IND SWIFT LABS:

IND SWIFT LABS momentum equity

Note: the dividends potentially given by IND SWIFT LABS are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IND SWIFT LABS

The following chart shows the employed capital evolution of the two momentum strategies on IND SWIFT LABS since the beginning:

IND SWIFT LABS

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250₹, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000₹.


Buy the dip strategy result on IND SWIFT LABS

Buy the dip entry openings on IND SWIFT LABS

IND SWIFT LABS

The performance achieved by the robo-advisor on IND SWIFT LABS is 0%. That represents 0.0$ of latent gain with 0.0₹ of employed capital. The following chart shows IND SWIFT LABS stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of IND SWIFT LABS, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 ₹

Invested capital

0.0 ₹

Annualized return

0.0 %

Equity curve of the strategy applied to IND SWIFT LABS

The following chart shows the result of the investment strategy applied to IND SWIFT LABS:

IND SWIFT LABS

Note: the dividends potentially given by IND SWIFT LABS are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IND SWIFT LABS

The following chart shows the employed capital evolution since the beginning of the investment strategy on IND SWIFT LABS:

IND SWIFT LABS

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on IND SWIFT LABS

In this section, I will compare the three previous investment strategies applied to IND SWIFT LABS.

Equity curve comparison on IND SWIFT LABS

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

IND SWIFT LABS investment strategy comparison

Employed capital comparison on IND SWIFT LABS

IND SWIFT LABS investment comparison

Performance comparison on IND SWIFT LABS

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 42.03% 1071.1₹ 2548.55₹ 9.96%
Momentum 1 quarter 41.1% 2233.85₹ 5434.9₹ 10.33%
Momentum 2 quarters 37.54% 786.95₹ 2096.5₹ 10.04%
Non-directional 0% 0.0₹ 0.0₹ 0.0%
Annualized return comparison

Automatic investment

9.96 %

Momentum 1Q

10.04 %

Momentum 2Q

10.04 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with IND SWIFT LABS:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between IND SWIFT LABS and the other stocks. There may be false positives or some missing correlated stocks. If the price of IND SWIFT LABS does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name IND SWIFT LABS
Country India
City Manimajra
Address Shivalik Enclave
Phone 91 17 2273 0503
Website www.indswiftlabs.com
FullTime employees
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XNSE
Ticker INDSWFTLAB.XNSE
Market

IND SWIFT LABS ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown